Navigation Links
Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
Date:9/3/2007

Inclusion of Gerresheimer Stock in the SDAX as Per September 6, 2007

Outside the Normal Schedule Decision on Possible Inclusion in the MDAX to be Taken on 5 September

DÜSSELDORF, Germany, September 3 /PRNewswire/ -- Gerresheimer AG has been listed in the Prime Standard of the Frankfurter Stock exchange since June 11, 2007, following one of the largest IPOs of the year, with a total issue volume of more than 900 million euros. Gerresheimer stock will be included in the SDAX index of Deutsche Borse, Frankfurt am Main, on September 6, 2007 outside the normal schedule.

Possible inclusion of Gerresheimer stock in the MDAX index is independent of this decision. Changes in the composition of the selection indices are to be published by Deutsche Borse this coming Wednesday, 5 September.

Dr. Axel Herberg, CEO of Gerresheimer AG, in welcoming the decision, says: "We are pleased that our stock is to be included in the SDAX outside the normal schedule after only three months on the stock exchange and thereby becomes even more attractive."

Gerresheimer is a pharmaceutical & life science supply and services company with market leading positions of specialty products made of glass and plastic. Gerresheimer owns 37 production sites in Europe, North America and Asia and employs approximately 10,000 employees worldwide.

Contact

Burkhard Lingenberg

Director Corporate PR & Marketing

Telefon +49-211-6181-250

Telefax +49-211-6181-241

e-mail b.lingenberg@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. The Dangers Of Vitamin A To Pregnant Women To Be Included On Label
2. Hepatitis B Vaccine To Be Included In National Immunization Programme
3. ISRO To Expand Telemedicine Network, 4 Speciality Hospitals To Be Included
4. Meningitis Vaccine To Be Included In Childhood Immunization Programme
5. Cervical Cancer Vaccine Gardasil Included In Subsidized CDC program
6. Eight More African Countries Included In US Malaria Program
7. Yoga, to Be Included in Schools as Part of the Curriculum
8. A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List
9. Gene linked to early puberty in girls
10. Cancer drugs in development nearly doubled since 1995
11. Nearly all asthma deaths preventable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...p://www.aronowitzmd.com [Los Angeles cosmetic sur...e in plastic surgery procedures for post bariatric...be necessary for these patients, health and wellne...pecialty of procedures for after weight loss. , ...ust 29, 2008 -- Bariatric surgery improves the hea...
(Date:8/28/2008)...onventional therapy, study found , , THU...a treadmill improves brain function and fitness fo...gh the usual rehabilitation program, a new study f...s have," said study researcher Dr. Andreas Luft, a...tation at the University of Zurich in Switzerland....
(Date:8/28/2008)...l efforts of the Maryland Medicaid contract, HARR...onal medical,management firm, appointed Lenaye Law...r. Dr. Lawyer will oversee all clinical aspects of...nt Valley, Maryland Harrisburg,office., "Dr. Lawy...land," said,Alice Stollenwerk Petrulis, MD, FACP, ...
(Date:8/28/2008)... physical, especially for the impaired, study says...-- A new study says that 13 percent of American se...use. , The University of Chicago researchers s... being taken advantage of financially (3.5 percent... found that seniors with physical impairments were...
Breaking Medicine News(10 mins):Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:Treadmill Workouts Help Stroke Survivors 2Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:13% of Seniors Report Being Mistreated 2
...sandro Remo Zanetti and his colleagues from Instit...ination with Hepatitis B produces the required con... of the patients for long periods//. The researche...inst Hepatitis B vaccination are present in the bl...
... infections are a major cause for hospitalization ...ection are risks for subsequent amputation. Ischem...betes combine to produce tissue necrosis and ulcer...lly polymicrobial in nature. Early recognition of ...
...morphins are highly powerful a tool for pain manag...rived from the opium poppy. It has previously been...erns// of side effects by virtue of their hard-wir...ceptors. Such receptors, known as u-opioids, appea...
... study conducted on factors that predispose to dri...’s tendency to do things like lie, steal or skip s...at a very early age of 12, 13 or 14//. The study ...the issue and is a contradiction to the existing a...
Other Medicine News:Health News:Booster dose not required for Hepatitis B Vaccination 2Health News:The Polymicrobial Nature Of Diabetic Foot Infections 2Health News:Ambiguous Efficacy Of Opioid Drugs In Chronic Inflammatory Joint Pain Relief 2
(Date:8/27/2008)...ght in Parts of Bucks, Delaware, Montgomery,Phila...swire-USNewswire/ -- After encouraging,results fol...epartment of,Environmental Protection will continu...gainst the mosquito-borne West Nile virus., Targe... 8 p.m. and,midnight in portions of Bucks, Delawar...
(Date:8/27/2008)...CADE, melphalan and prednisone arm demonstrated a,...cent complete response -, CAMBRIDGE, Mass., Aug. ... Company today announced the publication of result...A(1) trial in this week,s edition of the,New Engla...ficant survival,benefit and a 30 percent complete ...
(Date:8/27/2008)...st 27 /-, - Oralair(R) Gra...harmacodynamic Study Conducted in an Allergen Chal...ghly positive results of a new study,conducted in ...n Oralair(R) Grasses included 86 adult patients ex...atment durations: 1 week, 1 month,2 and 4 months ...
(Date:8/27/2008)...a, from BLISS-52 trial, expected by mid-2009 - - ... by fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewsw...daq: HGSI ) today announced it has completed enro...of two pivotal Phase 3,randomized clinical trials ...tive systemic lupus erythematosus (SLE). Belimumab...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 1Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 2Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 3Smokers Cost Medicaid System Nearly 2410 Billion 7170 1Smokers Cost Medicaid System Nearly 2410 Billion 7170 2Smokers Cost Medicaid System Nearly 2410 Billion 7170 3Sigma Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO IEC 17025 and ISO Guide 34 1992 1Sigma Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO IEC 17025 and ISO Guide 34 1992 2Meniscal damage and the development of persistent knee pain 7168 1Meniscal damage and the development of persistent knee pain 7168 2Meniscal damage and the development of persistent knee pain 7168 3
...ults Indicate Bioequivalent Pharmacokinetics With ...X-514, SAN DIEGO, April 25, 2007 /PRNewswire-First...rmaceutical research and,development company focus...es for the treatment of cancer and infectious dise...nical pharmacokinetic,testing of ANX-514 (docetaxe...
...SEL, Switzerland, April 25, 2007 - Basilea Pharmac...udy results showing that,patients with severe chro... alitretinoin. In two previous randomized clinical... treating severe,chronic hand eczema in patients r...l demonstrated that patients responsive to initial...
Other Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box.
Hydrodissection / Aspiration Cannula, 25 g. Straight with U-tip. U-shaped tip allows aspiration and irrigation at the 12 o'clock position. Overall length 18 mm. 5/box.
Silicone Capsule Polisher, 27 g. Silicon tip to provide squeegee effect. Overall length 22 mm. 5/box.
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box.
Medicine Products: